Drugs / [203Pb]Pb-PSV359
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06710756 | Apr 2025 → Jan 2028 expected | colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer +4 | Perspective Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [203Pb]Pb-PSV359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06710756 ↗ |
| Modality | Diagnostic / imaging agent | “for single-photon emission computed tomography imaging” NCT06710756 ↗ |
| Route | Intravenous | “administered by intravenous bolus injection” NCT06710756 ↗ |
| Target | FAP | “imaging FAP-expressing cancers” NCT06710756 ↗ |